Document is current
Any future updates will be listed below
-
Authors
Ng, Benjamin
Widjaja, Anissa A.
Viswanathan, Sivakumar
Dong, Jinrui
Chothani, Sonia P.
Lim, Stella
Shekeran, Shamini G.
Tan, Jessie
McGregor, Narelle E.
Walker, Emma C.
Sims, Natalie A.
Schafer, Sebastian
Cook, Stuart A.
-
Funding
Funding for this research was provided by:
National Medical Research Council (NMRC/OFYIRG/0053/2017, NMRC/OFYIRG18nov-0014, NMRC/STaR/0029/2017)
- License Information
-
More Information
Article History
Received: 5 November 2020
Accepted: 21 June 2021
First Online: 8 July 2021
Competing interests
: S.A.C. and S.S. are co-inventors of the patent applications (WO2017103108, WO2017103108 A2, WO 2018/109174 A2, WO 2018/109170 A2) for “Treatment of fibrosis”. A.A.W., S. S. and S.A.C. are co-inventors of the patent applications (GB1900811.9, GB 1902419.9, GB1906597.8) for “Treatment of hepatotoxicity, nephrotoxicity, and metabolic diseases''. S. S., S. A.C. and B.N. are co-inventors of the patent application (WO/2019/073057) for “Treatment of SMC mediated disease”. S.A.C. and S.S. are co-founders and shareholders of Enleofen Bio Pte. Ltd., a company that made anti-IL11 therapeutics, which were acquired for further development by Boehringer Ingelheim. All other co-authors declare no competing interests.
